STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D000077285:Rimonabant; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
D019440:Anti-Obesity Agents; D002317:Cardiovascular Agents; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant